ERBB3 and neoplasm: When administered at a dose and schedule equivalent to that used for preclinical testing of an anti-ERBB3 antibody that has progressed to clinical development [13], the A5/F4 oligoclonal (20 mg/Kg each, BIW) significantly reduced (p = 0.004) tumor growth rates as compared to vehicle treatment (Figure 6A).